Kerri Fitzgerald

Cancer Nursing Today nonprod

The CALR&nbsp;mutation has prognostic value for the stratification of thrombotic risk in patients with essential thrombocytopenia (ET), according to a study published in the European Journal of Haematology.Researchers retrospectively assessed 983 patients with ET diagnosed in Spanish and Polish hospitals. After a median 7.5&nbsp;years of follow?up from diagnosis, 155 patients (15.8%) had one or more thrombotic event.Five?year thrombosis?free survival (TFS) rate was 83.8% for patients with the JAK2 V617F mutation, 91.6% for those with CALR-type 1 mutation, and 93.9% for those with&nbsp;CALR?type 2 mutations (P=0.002).TFS for venous thrombosis was lower in&nbsp;CALR?type 1 mutations (P=0.046), with there was no difference in TFS for arterial thrombosis. The cumulative incidence of thrombosis was significantly different when comparing patients with&nbsp;JAK2 V617F versus&nbsp;CALR?type 2 mutations. However, this associated was not observed between patients with JAK2 V617F versus&nbsp;CALR?type 1 mutations.In multivariate logistic regression models, when adjusted by age, CALR?type 2 mutation was a statistically significant protective factor for thrombosis with respect to&nbsp;JAK2 V617F mutation (odds ratio, 0.45;&nbsp;P=0.04).

CALR Mutation and Thrombotic Risk in Patients with Essential Thrombocytopenia

Hematology & Blood Cancer

The CALR mutation has prognostic value for the stratification of thrombotic risk in patients with essential thrombocytopenia (ET), according to a study published in the European Journal of Haematology. Researchers retrospectively assessed 983 patients with ET diagnosed in Spanish and Polish hospitals. After a median 7.5 years of follow?up from diagnosis, 155 patients (15.8%) had one or [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe